Real-world study demonstrates that telitacicept improves eGFR outcomes in IgA nephropathy, suggesting better treatment options.
Conclusion:In this real-world study, low-to medium-dose of telitacicept combined with conventional therapy showed good onset efficacy and safety for treating IgA patients.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.
No takes yet. Share an insight, caveat, or question.
Hosotani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: